Review of GLP-1 drug implications for perioperative management covers anesthesia considerations, gastric residual volumes, surgical outcomes, and medication management around procedures.
Key findingReview of GLP-1 drug implications for perioperative management covers anesthesia considerations, gas
What the researchers found
Review of GLP-1 drug implications for perioperative management covers anesthesia considerations, gastric residual volumes, surgical outcomes, and medication management around procedures.
Why it matters
Relevant to expanding peptide-based therapeutic applications.
The numbers in context
Review examining the bidirectional association between periodontitis and diabetes/obesity, and how GLP-1 drugs may influence this relationship.
How the study worked
Methodology detailed in publication.
Who was studied
Review discussing patients with diabetes, obesity, and periodontal disease
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing evidence for peptide therapeutics.
Questions still open
- Long-term implications?
- Comparison to existing evidence?
- Next research steps?
Common questions
What does this mean?
How reliable?
Read the original research
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry.
Cureus, 17(10), e95792
Citation
Almohammad, Asmaa A; Aldossari, Sara K; Sukumbaji, Ziyad A; Faden, Raniah A; Almutairi, Mona A; Al-Harbi, Noura H; Al-Saaib, Majida Y; Almarshedy, Bandary S; Alharabi, Entesar A; Alhazri, Wafaa A; Altalhi, Abdulaziz M. (2025). Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry.. Cureus, 17(10), e95792. https://doi.org/10.7759/cureus.95792